Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanomeline-trospium for cognitive impairment in early psychosis
ISRCTN59554792Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of xanomeline, trospium, risperidone, lurasidone in schizophrenia, schizoaffective disorder, schizophreniform disorder, sponsored by University of Oxford. Started Jun 2026; status: recruiting.
02
Drugs
xanomelinetrospiumrisperidonelurasidone
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on ISRCTN59554792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59554792.